
    
      This is a Phase 2, two-arm, randomized, placebo-controlled, double-blind, multicenter study
      of relapsed/refractory multiple myeloma patients who have received at least two prior
      therapies, including a proteasome inhibitor and an IMiD.

      Patients who meet all the eligibility criteria will be randomized to one of two blinded
      treatment arms:

        -  selinexor + carfilzomib + dexamethasone

        -  placebo + carfilzomib + dexamethasone
    
  